CALIFORNIA LEGISLATURE 20192020 REGULAR SESSION Assembly Bill No. 319Introduced by Assembly Members Blanca Rubio and Waldron(Coauthor: Senator Stone)January 30, 2019 An act to amend Section 11839.2 of the Health and Safety Code, relating to controlled substances. LEGISLATIVE COUNSEL'S DIGESTAB 319, as introduced, Blanca Rubio. Narcotic treatment: medication-assisted treatment.Existing law requires the State Department of Health Care Services to license narcotic treatment programs to use narcotic replacement therapy and medication-assisted treatment in the treatment of addicted persons. Existing law specifies the medications a licensed narcotic treatment program may use for narcotic replacement therapy and medication-assisted treatment by licensed narcotic treatment programs.This bill would require the department to create reimbursement rates and rate billing codes for use by licensed narcotic treatment programs providing medication-assisted treatment using noncontrolled medications approved by the Food and Drug Administration for patients with a substance use disorder.Digest Key Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: NO Bill TextThe people of the State of California do enact as follows:SECTION 1. Section 11839.2 of the Health and Safety Code is amended to read:11839.2. The following medications are authorized for use in narcotic replacement therapy and medication-assisted treatment by licensed narcotic treatment programs:(a) Methadone.(b) Levo-alpha-acetylmethadol (LAAM) as specified in paragraph (10) of subdivision (c) of Section 11055.(c) Buprenorphine products or combination of products approved by the federal Food and Drug Administration for maintenance or detoxification of opioid dependence.(d) Any other medication approved by the federal Food and Drug Administration for the purpose of narcotic replacement treatment or medication-assisted treatment of substance use disorders. The department shall establish reimbursement rates and rate billing codes for medication-assisted treatment services provided by licensed narcotic treatment programs electing to provide noncontrolled medications approved by the Food and Drug Administration for patients with a substance use disorder pursuant to this section.(e) Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section by means of plan or provider bulletins, or similar instructions. The department shall adopt regulations by no later than January 1, 2021.
CALIFORNIA LEGISLATURE 20192020 REGULAR SESSION Assembly Bill No. 319Introduced by Assembly Members Blanca Rubio and Waldron(Coauthor: Senator Stone)January 30, 2019 An act to amend Section 11839.2 of the Health and Safety Code, relating to controlled substances. LEGISLATIVE COUNSEL'S DIGESTAB 319, as introduced, Blanca Rubio. Narcotic treatment: medication-assisted treatment.Existing law requires the State Department of Health Care Services to license narcotic treatment programs to use narcotic replacement therapy and medication-assisted treatment in the treatment of addicted persons. Existing law specifies the medications a licensed narcotic treatment program may use for narcotic replacement therapy and medication-assisted treatment by licensed narcotic treatment programs.This bill would require the department to create reimbursement rates and rate billing codes for use by licensed narcotic treatment programs providing medication-assisted treatment using noncontrolled medications approved by the Food and Drug Administration for patients with a substance use disorder.Digest Key Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: NO
CALIFORNIA LEGISLATURE 20192020 REGULAR SESSION
Assembly Bill No. 319
Introduced by Assembly Members Blanca Rubio and Waldron(Coauthor: Senator Stone)January 30, 2019
Introduced by Assembly Members Blanca Rubio and Waldron(Coauthor: Senator Stone)
January 30, 2019
An act to amend Section 11839.2 of the Health and Safety Code, relating to controlled substances.
LEGISLATIVE COUNSEL'S DIGEST
## LEGISLATIVE COUNSEL'S DIGEST
AB 319, as introduced, Blanca Rubio. Narcotic treatment: medication-assisted treatment.
Existing law requires the State Department of Health Care Services to license narcotic treatment programs to use narcotic replacement therapy and medication-assisted treatment in the treatment of addicted persons. Existing law specifies the medications a licensed narcotic treatment program may use for narcotic replacement therapy and medication-assisted treatment by licensed narcotic treatment programs.This bill would require the department to create reimbursement rates and rate billing codes for use by licensed narcotic treatment programs providing medication-assisted treatment using noncontrolled medications approved by the Food and Drug Administration for patients with a substance use disorder.
Existing law requires the State Department of Health Care Services to license narcotic treatment programs to use narcotic replacement therapy and medication-assisted treatment in the treatment of addicted persons. Existing law specifies the medications a licensed narcotic treatment program may use for narcotic replacement therapy and medication-assisted treatment by licensed narcotic treatment programs.
This bill would require the department to create reimbursement rates and rate billing codes for use by licensed narcotic treatment programs providing medication-assisted treatment using noncontrolled medications approved by the Food and Drug Administration for patients with a substance use disorder.
## Digest Key
## Bill Text
The people of the State of California do enact as follows:SECTION 1. Section 11839.2 of the Health and Safety Code is amended to read:11839.2. The following medications are authorized for use in narcotic replacement therapy and medication-assisted treatment by licensed narcotic treatment programs:(a) Methadone.(b) Levo-alpha-acetylmethadol (LAAM) as specified in paragraph (10) of subdivision (c) of Section 11055.(c) Buprenorphine products or combination of products approved by the federal Food and Drug Administration for maintenance or detoxification of opioid dependence.(d) Any other medication approved by the federal Food and Drug Administration for the purpose of narcotic replacement treatment or medication-assisted treatment of substance use disorders. The department shall establish reimbursement rates and rate billing codes for medication-assisted treatment services provided by licensed narcotic treatment programs electing to provide noncontrolled medications approved by the Food and Drug Administration for patients with a substance use disorder pursuant to this section.(e) Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section by means of plan or provider bulletins, or similar instructions. The department shall adopt regulations by no later than January 1, 2021.
The people of the State of California do enact as follows:
## The people of the State of California do enact as follows:
SECTION 1. Section 11839.2 of the Health and Safety Code is amended to read:11839.2. The following medications are authorized for use in narcotic replacement therapy and medication-assisted treatment by licensed narcotic treatment programs:(a) Methadone.(b) Levo-alpha-acetylmethadol (LAAM) as specified in paragraph (10) of subdivision (c) of Section 11055.(c) Buprenorphine products or combination of products approved by the federal Food and Drug Administration for maintenance or detoxification of opioid dependence.(d) Any other medication approved by the federal Food and Drug Administration for the purpose of narcotic replacement treatment or medication-assisted treatment of substance use disorders. The department shall establish reimbursement rates and rate billing codes for medication-assisted treatment services provided by licensed narcotic treatment programs electing to provide noncontrolled medications approved by the Food and Drug Administration for patients with a substance use disorder pursuant to this section.(e) Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section by means of plan or provider bulletins, or similar instructions. The department shall adopt regulations by no later than January 1, 2021.
SECTION 1. Section 11839.2 of the Health and Safety Code is amended to read:
### SECTION 1.
11839.2. The following medications are authorized for use in narcotic replacement therapy and medication-assisted treatment by licensed narcotic treatment programs:(a) Methadone.(b) Levo-alpha-acetylmethadol (LAAM) as specified in paragraph (10) of subdivision (c) of Section 11055.(c) Buprenorphine products or combination of products approved by the federal Food and Drug Administration for maintenance or detoxification of opioid dependence.(d) Any other medication approved by the federal Food and Drug Administration for the purpose of narcotic replacement treatment or medication-assisted treatment of substance use disorders. The department shall establish reimbursement rates and rate billing codes for medication-assisted treatment services provided by licensed narcotic treatment programs electing to provide noncontrolled medications approved by the Food and Drug Administration for patients with a substance use disorder pursuant to this section.(e) Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section by means of plan or provider bulletins, or similar instructions. The department shall adopt regulations by no later than January 1, 2021.
11839.2. The following medications are authorized for use in narcotic replacement therapy and medication-assisted treatment by licensed narcotic treatment programs:(a) Methadone.(b) Levo-alpha-acetylmethadol (LAAM) as specified in paragraph (10) of subdivision (c) of Section 11055.(c) Buprenorphine products or combination of products approved by the federal Food and Drug Administration for maintenance or detoxification of opioid dependence.(d) Any other medication approved by the federal Food and Drug Administration for the purpose of narcotic replacement treatment or medication-assisted treatment of substance use disorders. The department shall establish reimbursement rates and rate billing codes for medication-assisted treatment services provided by licensed narcotic treatment programs electing to provide noncontrolled medications approved by the Food and Drug Administration for patients with a substance use disorder pursuant to this section.(e) Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section by means of plan or provider bulletins, or similar instructions. The department shall adopt regulations by no later than January 1, 2021.
11839.2. The following medications are authorized for use in narcotic replacement therapy and medication-assisted treatment by licensed narcotic treatment programs:(a) Methadone.(b) Levo-alpha-acetylmethadol (LAAM) as specified in paragraph (10) of subdivision (c) of Section 11055.(c) Buprenorphine products or combination of products approved by the federal Food and Drug Administration for maintenance or detoxification of opioid dependence.(d) Any other medication approved by the federal Food and Drug Administration for the purpose of narcotic replacement treatment or medication-assisted treatment of substance use disorders. The department shall establish reimbursement rates and rate billing codes for medication-assisted treatment services provided by licensed narcotic treatment programs electing to provide noncontrolled medications approved by the Food and Drug Administration for patients with a substance use disorder pursuant to this section.(e) Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section by means of plan or provider bulletins, or similar instructions. The department shall adopt regulations by no later than January 1, 2021.
11839.2. The following medications are authorized for use in narcotic replacement therapy and medication-assisted treatment by licensed narcotic treatment programs:
(a) Methadone.
(b) Levo-alpha-acetylmethadol (LAAM) as specified in paragraph (10) of subdivision (c) of Section 11055.
(c) Buprenorphine products or combination of products approved by the federal Food and Drug Administration for maintenance or detoxification of opioid dependence.
(d) Any other medication approved by the federal Food and Drug Administration for the purpose of narcotic replacement treatment or medication-assisted treatment of substance use disorders. The department shall establish reimbursement rates and rate billing codes for medication-assisted treatment services provided by licensed narcotic treatment programs electing to provide noncontrolled medications approved by the Food and Drug Administration for patients with a substance use disorder pursuant to this section.
(e) Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section by means of plan or provider bulletins, or similar instructions. The department shall adopt regulations by no later than January 1, 2021.